Bleakley Financial Group’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Bleakley Financial Group’s Portfolio NYMX Stock Details NYMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-80,000	Closed	-$15.2K	–	970
2023 Q2	$15.2K	Hold	80,000	–	–	﹤0.01%	920
2023 Q1	$27.2K	Hold	80,000	–	–	﹤0.01%	889
2022 Q4	$23.8K	Buy	+80,000	New	+$29K	﹤0.01%	858

Other funds holding NYMX

DDC

DF Dent & Co Baltimore, Maryland $5.27B AUM 7.89% 1-Year Est. Return

FCFC

First Citizens Financial Corp Mason City, Iowa $239M AUM 26.56% 1-Year Est. Return

CAM

Cubic Asset Management Boston, Massachusetts $422M AUM 29.18% 1-Year Est. Return

ODIJL

One Day In July LLC Burlington, Vermont $1.44B AUM 17.18% 1-Year Est. Return

Bleakley Financial Group's NYMX Position: Q3 2023 in Review

Bleakley Financial Group sold out of Nymox Pharmaceutical Corp (NYMX) in Q3 2023, closing a stake of 80,000 shares — an estimated $15.2K sold.

Bleakley Financial Group first reported a position in NYMX in Q4 2022 and held it in 3 quarters. The position peaked at $27.2K in Q1 2023. 5 funds tracked by Wall St. Rank hold NYMX as of Q3 2023.

Bleakley Financial Group reported no remaining Nymox Pharmaceutical Corp position as of Q3 2023 after selling out during the quarter.
Bleakley Financial Group sold 80,000 Nymox Pharmaceutical Corp shares in Q3 2023, an estimated $15.2K.
Bleakley Financial Group first reported a position in Nymox Pharmaceutical Corp in Q4 2022 and held it in 3 quarters.
Bleakley Financial Group's Nymox Pharmaceutical Corp position peaked at $27.2K in Q1 2023.
5 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2023.

Based on Bleakley Financial Group's 13F filing for Q3 2023, filed 14 Nov 2023.